Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2021 | Unmet needs in CML

Joaquin Martinez-Lopez • 10 Sep 2021
IMW 2021
Chronic Myeloid Leukemia Leukemia Ponatinib

Joaquin Martinez-Lopez, MD, PhD, of the Universidad Complutense de Madrid, Madrid, Spain, gives an overview of the unmet needs in the treatment of chronic myeloid leukemia (CML). Dr Martinez-Lopez focuses on two main clinically unmet needs: long-term toxicities and treatment resistance in CML, and explains how future research may address these. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

Disclosures

Joaquin Martinez-Lopez, MD, PhD, has received grant support from BMS; and has performed consultancy work for BMS, Janssen, Novartis, GSK, Incyte, Roche and Astellas.

More from Joaquin Martinez-Lopez

Laboratory techniques used for immune evaluation in multiple myeloma
1:26
Laboratory techniques used for immune evaluation in multiple myeloma
Joaquin Martinez-Lopez • 25 Aug 2022
Infectious toxicities in patients with multiple myeloma treated with bispecific antibodies
1:19
Infectious toxicities in patients with multiple myeloma treated with bispecific antibodies
Joaquin Martinez-Lopez • 25 Aug 2022
Manufacturing allogeneic CAR-NKs for the treatment of multiple myeloma
1:04
Manufacturing allogeneic CAR-NKs for the treatment of multiple myeloma
Joaquin Martinez-Lopez • 25 Aug 2022
COVID-19 in myeloma: what have we learnt?
5:53
COVID-19 in myeloma: what have we learnt?
Joaquin Martinez-Lopez • 10 Sep 2021

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals